Alnylam Pharmaceuticals (ALNY) Given Buy Rating at Piper Jaffray Companies

Piper Jaffray Companies reaffirmed their buy rating on shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) in a research note released on Sunday morning. They currently have a $182.00 price objective on the biopharmaceutical company’s stock.

ALNY has been the subject of a number of other research reports. Credit Suisse Group lifted their price target on shares of Alnylam Pharmaceuticals from $123.00 to $151.00 and gave the stock an outperform rating in a research note on Friday, November 3rd. B. Riley started coverage on shares of Alnylam Pharmaceuticals in a research note on Wednesday, November 1st. They issued a buy rating and a $240.00 price target for the company. Nomura started coverage on shares of Alnylam Pharmaceuticals in a research note on Thursday, September 14th. They issued a reduce rating and a $56.00 price target for the company. Chardan Capital restated a buy rating on shares of Alnylam Pharmaceuticals in a research note on Monday, September 11th. Finally, Goldman Sachs Group upgraded shares of Alnylam Pharmaceuticals from a buy rating to a conviction-buy rating in a research note on Friday, December 15th. Three analysts have rated the stock with a sell rating, seven have assigned a hold rating, fifteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. Alnylam Pharmaceuticals currently has an average rating of Buy and an average target price of $121.20.

Shares of Alnylam Pharmaceuticals (ALNY) traded up $1.45 during trading hours on Friday, hitting $129.18. 1,129,800 shares of the company were exchanged, compared to its average volume of 1,080,000. The company has a current ratio of 9.83, a quick ratio of 9.83 and a debt-to-equity ratio of 0.14. The company has a market capitalization of $12,700.00, a price-to-earnings ratio of -24.61 and a beta of 2.98. Alnylam Pharmaceuticals has a fifty-two week low of $35.98 and a fifty-two week high of $147.63.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($1.34) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.23) by ($0.11). The company had revenue of $17.10 million during the quarter, compared to the consensus estimate of $28.15 million. Alnylam Pharmaceuticals had a negative return on equity of 46.94% and a negative net margin of 664.70%. The firm’s quarterly revenue was up 24.8% on a year-over-year basis. During the same quarter last year, the firm posted ($1.21) EPS. analysts forecast that Alnylam Pharmaceuticals will post -5.21 earnings per share for the current fiscal year.

In other news, VP Michael Mason sold 36,745 shares of the company’s stock in a transaction dated Thursday, January 4th. The shares were sold at an average price of $131.59, for a total transaction of $4,835,274.55. Following the completion of the transaction, the vice president now owns 6,352 shares in the company, valued at $835,859.68. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO John Maraganore sold 74,000 shares of the company’s stock in a transaction dated Wednesday, November 15th. The stock was sold at an average price of $126.86, for a total transaction of $9,387,640.00. Following the transaction, the chief executive officer now owns 223,710 shares of the company’s stock, valued at approximately $28,379,850.60. The disclosure for this sale can be found here. In the last quarter, insiders have sold 274,075 shares of company stock valued at $35,356,089. 4.30% of the stock is owned by insiders.

Several institutional investors have recently added to or reduced their stakes in the company. FMR LLC grew its position in shares of Alnylam Pharmaceuticals by 6.3% during the second quarter. FMR LLC now owns 13,723,153 shares of the biopharmaceutical company’s stock worth $1,094,559,000 after acquiring an additional 815,270 shares during the last quarter. Vanguard Group Inc. grew its position in shares of Alnylam Pharmaceuticals by 13.4% during the second quarter. Vanguard Group Inc. now owns 6,419,508 shares of the biopharmaceutical company’s stock worth $512,020,000 after acquiring an additional 759,295 shares during the last quarter. BlackRock Inc. grew its position in shares of Alnylam Pharmaceuticals by 9.3% during the second quarter. BlackRock Inc. now owns 5,188,191 shares of the biopharmaceutical company’s stock worth $413,811,000 after acquiring an additional 441,957 shares during the last quarter. Orbimed Advisors LLC grew its position in shares of Alnylam Pharmaceuticals by 69.7% during the third quarter. Orbimed Advisors LLC now owns 1,084,800 shares of the biopharmaceutical company’s stock worth $127,453,000 after acquiring an additional 445,600 shares during the last quarter. Finally, First Trust Advisors LP grew its position in shares of Alnylam Pharmaceuticals by 25.3% during the third quarter. First Trust Advisors LP now owns 784,619 shares of the biopharmaceutical company’s stock worth $92,185,000 after acquiring an additional 158,288 shares during the last quarter. Institutional investors and hedge funds own 88.39% of the company’s stock.

WARNING: This report was originally posted by Transcript Daily and is owned by of Transcript Daily. If you are reading this report on another domain, it was illegally copied and republished in violation of United States & international trademark and copyright law. The original version of this report can be viewed at https://transcriptdaily.com/2018/01/09/alnylam-pharmaceuticals-alny-given-buy-rating-at-piper-jaffray-companies.html.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).

Analyst Recommendations for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply